Eastern Pulmonary Conference 2017

Palm Beach, FL US
August 31, 2017 to September 3, 2017

Didactic lectures allow speakers to provide evidence based medical recommendations, updates and expert opinion in an efficient manner.  

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Pulmonary Conference (EPC 2017).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  14.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding
This activity is supported by independent educational grants from AstraZeneca, Circassia and Teva.

Target Audience

Practicing allergists, fellows-in-training, primary care physicians and allied healthcare providers in the field of allergy.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Discuss the causes and consequences of fixed airflow obstruction in asthma and recognize the concept of airway remodeling
  • Outline the different phenotypic expressions of asthma such as eosinophilic-driven asthma, pauci-immune asthma  and neutrophilic asthma.
  • Discuss the phenotype of aspirin-exacerbated asthma and apply current understanding of this condition to disease recognition and treatment of this condition
  • Describe the use of biomarkers to guide the current and future treatment options for asthma and discuss the optimal approaches to severe persistent asthma.
  • Explain the clinical presentations, treatments and outcomes of the non-infectious pneumonia: hypersensitivity pneumonitis
Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Dana Ascherman, MD - Speaker

Nothing to Disclose

Mary Beth Beasley, MD - Speaker

Consultant: Genentech, Merck, Bristol Myer Squibb

Sidney Braman, MD – Planner, Moderator, Speaker

Advisory Board: AstraZeneca, Sunovion

Speaker:  Genentech

Don Bukstein, MD - Speaker

Speaker: Circassia, AstraZeneca, Novartis, Genentech, Mylan, Teva

Geoff Chupp, MD - Speaker

Advisory Board: AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Genentech

Speaker: AstraZeneca, Boston Scientific, Circassia, Genentech

Research: AstraZeneca,

Author: GlaxoSmithKline, Boston Scientific

William Corrao, MD – Moderator, Speaker

Speaker: Boehringer Ingelheim

Advisory Board: GlaxoSmithKline

Marilyn Glassberg, MD – Speaker

Advisory Board: Boehringer Ingelheim, Genentech

Consultant: Bellerophon

Catherine Kier, MD - Speaker

Nothing to Disclose

James Klinger, MD – Speaker

Independent Contractor:  Actelion, Lung International, Eiger

Consultant: Bayer

Barry Make, MD - Speaker

Consultant: AstraZeneca, Sunovion

Speaker: AstraZeneca, Sunovion

Advisory Board: AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Verona, Sunovion

Independent Contractor: AstraZeneca, Spiration, Glassia

Lawrence Mohr, MD – Speaker

Nothing to Disclose

Michael Neiderman, MD – Speaker

Consultant: Pfizer, Merck, Bayer

Research: Bayer

Rey Panettieri Jr., MD – Planner, Moderator, Speaker

Advisory Board: AstraZeneca, Med Immune, Novartis, RIFM

Speaker: AstraZeneca, Teva

Independent Contractor: AstraZeneca, Novartis, Theratrophix, Oncoarendi, Amgen, Vertex, Bristol Myer Squibb

Suhail Raoof, MD – Speaker

Nothing to Disclose

Mary Salvatore, MD - Speaker

Speaker: Genentech, Boehringer Ingelheim, Rockpoint

Author: Rockpoint 

Russell Settipane, MD – Planner, Moderator, Speaker, Reviewer

Advisory Board: AstraZeneca, Genentech, Novartis, Merck, Teva, Alk, Circassia, Sanofi/Regeneron, CSL Behring

Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Novartis, Stallergenes/Greer, Merck, Mylan, Teva, Shire, Pharming

Independent Contractor: Genentech, Novartis, Stallergenes/Greer, Merck, Teva 

Ginny Loiselle – Coordinator

Nothing to disclose

Course summary
Available credit: 
  • 14.75 AMA PRA Category 1 Credit™
  • 14.75 Attendance
Course opens: 
08/31/2017
Course expires: 
09/03/2019
Event starts: 
08/31/2017 - 3:30pm
Event ends: 
09/03/2017 - 10:30am
Cost:
$0.00
Rating: 
0
The Breakers
1 S. County Road
Palm Beach, FL 33480
United States

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Pulmonary Conference (EPC 2017).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  14.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding
This activity is supported by independent educational grants from AstraZeneca, Circassia and Teva.

Available Credit

  • 14.75 AMA PRA Category 1 Credit™
  • 14.75 Attendance

Accreditation Period

Course opens: 
08/31/2017
Course expires: 
09/03/2019

Price

Cost:
$0.00
Please login or create an account to take this course.